Real-World Experience of Angiotensin Receptor–Neprilysin Inhibition in Reduced Ejection Fraction Heart Failure Patients With Advanced Kidney Disease

射血分数 医学 心力衰竭 内科学 心脏病学 肾功能 心房颤动 肾脏疾病 倾向得分匹配 血管紧张素受体 血管紧张素II 血压
作者
Hung‐Yu Chang,Chun‐Cheng Lin,Chieh‐Ju Chao,Yi Lin,Yao-Chang Wang,Chia‐Te Liao,Jin‐Long Huang,Ying‐Hsiang Lee,Chun‐Yao Huang,Li‐Nien Chien,Chien‐Yi Hsu
出处
期刊:Mayo Clinic Proceedings [Elsevier BV]
卷期号:98 (1): 88-99 被引量:20
标识
DOI:10.1016/j.mayocp.2022.06.007
摘要

Objective To investigate the effectiveness and safety of angiotensin receptor-neprilysin inhibitors (ARNIs) in real-world patients with heart failure with reduced ejection fraction (HFrEF) and advanced chronic kidney disease (estimated glomerular filtration rate [eGFR] < 30 mL/min per 1.73 m2), which have been excluded from the landmark trials. Patients and Methods This study examined 3281 patients pooled from two multicenter HFrEF cohorts, and 661 patients with baseline eGFR less than 30 mL/min per 1.73 m2 were further analyzed (the Taiwan Society of Cardiology – Heart Failure with reduced Ejection Fraction (TSOC-HFrEF) registry: May 1, 2013 to October 31, 2014, and the Treatment with Angiotensin Receptor neprilysin inhibitor fOr Taiwan Heart Failure patients (TAROT-HF) study: March 1, 2017, to December 31, 2018). Propensity score matching was performed to adjust for confounders. At 1-year follow-up, all-cause mortality, total heart failure hospitalizations, renal function, and left ventricular ejection fraction (LVEF) were used as the endpoints. Results After propensity score matching, 510 patients (age, 69.8±13.9 years; male, 61.0%; mean LVEF, 29.8±7.3%; mean eGFR, 19.8±9.0 mL/min per 1.73 m2) were included in the final analysis, including 278 patients receiving ARNI treatment (ARNI group) and 232 patients not on ARNI treatment (non-ARNI group). Baseline characteristics were comparable between the two groups. At 1 year, eGFR and LVEF measurements were significantly higher in the ARNI group than in the non-ARNI group (25.0±17.1 mL/min per 1.73 m2 vs 21.4±17.5 mL/min per 1.73 m2; P=.04; and 40.1±12.9% vs. 33.1±10.8%, P<.001, respectively). The ARNI group had significantly lower risks of 1-year all-cause mortality (19.4 vs 30.9 per 100-person year; P=.02), and total HF rehospitalizations (70.0 vs 110.4 per 100-person year; P=.01) than non-ARNI users. Conclusion Our results show the effectiveness of ARNIs in HFrEF patients with advanced chronic kidney disease in a real-world setting.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
徐枘发布了新的文献求助10
1秒前
大个的应助被积极的含灵采纳,获得10
1秒前
3秒前
3秒前
banana的应助被与可采纳,获得10
4秒前
felix完成签到,获得积分10
4秒前
zqy发布了新的文献求助10
4秒前
5秒前
DYY完成签到,获得积分10
5秒前
阳光小虾米完成签到 ,获得积分10
5秒前
fairytaler的应助被yjt采纳,获得10
6秒前
6秒前
木木发布了新的文献求助10
7秒前
董ww发布了新的文献求助10
7秒前
科研通AI6.3的应助被禾木呈采纳,获得10
7秒前
xixi发布了新的文献求助10
8秒前
渭阳野士完成签到,获得积分10
8秒前
请赐我一篇Nature完成签到,获得积分10
8秒前
HH完成签到,获得积分10
9秒前
10秒前
10秒前
11秒前
耍酷迎海完成签到,获得积分20
12秒前
12秒前
XFF发布了新的文献求助10
13秒前
怂宝儿完成签到,获得积分10
14秒前
yhb发布了新的文献求助10
15秒前
15秒前
康康XY完成签到 ,获得积分10
16秒前
无极微光的应助被义气的雪糕采纳,获得20
16秒前
小蘑菇的应助被速写采纳,获得10
16秒前
所所的应助被清风徐来采纳,获得10
16秒前
羊大完成签到,获得积分10
16秒前
摇钱树发布了新的文献求助10
16秒前
科研通AI6.4的应助被清秀送终采纳,获得10
18秒前
852的应助被李晨语采纳,获得10
18秒前
FashionBoy的应助被dxftx采纳,获得10
18秒前
青争发布了新的文献求助10
19秒前
20秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184156
求助须知:如何正确求助?哪些是违规求助? 9573231
关于积分的说明 21830220
捐赠科研通 7781184
什么是DOI,文献DOI怎么找? 3434230
关于科研通互助平台的介绍 2558353
邀请新用户注册赠送积分活动 2480728